Orthocell easily raises $13 million
Nerve technology developer Orthocell (ASX:OCC) has received firm commitments from institutional investors to raise $13 million in a share placement. The company, which is commercialising its CelGro nerve regeneration product, received commitments for well in excess of the figure sought from existing and new investors. The company will also proceed with a share purchase plan…